Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Public priorities for primary care in Canada: Report on insights and actionable recommendations from 5 provincial reference panels.

Canadian family physician Medecin de famille canadien·2025
Same author

Primary cancer prevention for cancers with no known infectious etiology: Time for a new paradigm.

Vaccine·2024
Same author

Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines.

Vaccine·2024
Same author

Serious adverse events following mRNA vaccination in randomized trials in adults.

Vaccine·2023
Same author

Workshop Report: Catalyzing Knowledge-Driven Discovery in Environmental Health Sciences through a Harmonized Language.

International journal of environmental research and public health·2023
Same author

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020.

Vaccine·2022
Same journal

Effect of Preferred Language on Pediatric Rapid Response Activation and Subsequent Intensive Care Utilization.

Clinical pediatrics·2026
Same journal

Documented Caregiver Report of Wheezing at Home is Associated With Decreased Length of Pediatric Asthma Hospitalizations.

Clinical pediatrics·2026
Same journal

The Rash That Will Not Go Away.

Clinical pediatrics·2026
Same journal

Virtual Reality Education for Hospitalized Pediatric Patients Improves Intrinsic Motivation: A Prospective, Randomized Crossover Study.

Clinical pediatrics·2026
Same journal

Pediatric Invasive Group A Streptococcus Characteristics Before, During, and After COVID-19.

Clinical pediatrics·2026
Same journal

Lichen Sclerosus: A Common but Often Overlooked Condition in Pediatric Patients.

Clinical pediatrics·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Optimizing protection against meningococcal disease.

Keith S Reisinger1, Steven Black, Jeffrey J Stoddard

  • 1Primary Physicians Research, Pittsburgh, PA, USA. ksrppr@aol.com

Clinical Pediatrics
|January 22, 2010
PubMed
Summary
This summary is machine-generated.

An investigational meningococcal vaccine shows promise for infants, a critical age group for invasive meningococcal disease. This new vaccine could offer protection where current options are limited.

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
08:47

Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens

Published on: April 5, 2019

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Neisseria meningitidis is a primary cause of bacterial meningitis and septicemia in the US.
  • Current meningococcal vaccines (quadrivalent A, C, W-135, Y) are not approved for children under two.
  • Infants face the highest incidence of invasive meningococcal disease across all serogroups.

Purpose of the Study:

  • To evaluate the potential of an investigational quadrivalent (ACWY) meningococcal CRM(197) glycoconjugate vaccine for infant immunization.
  • To address the need for effective vaccines in infants, who are most vulnerable to meningococcal disease.

Main Methods:

  • Studies involved an investigational quadrivalent (ACWY) meningococcal CRM(197) glycoconjugate vaccine.
  • Evaluation focused on infants and toddlers younger than 2 years of age.

Main Results:

  • The investigational vaccine demonstrated potential efficacy in protecting infants against meningococcal disease.
  • Results suggest the vaccine could be suitable for routine infant immunization programs.

Conclusions:

  • An effective meningococcal vaccine for infants is crucial due to high disease incidence in this age group.
  • The investigational ACWY meningococcal CRM(197) glycoconjugate vaccine shows promise for protecting infants and toddlers.